ATHE Alterity publishes latest quarterly earnings report outlining new advancement plans for its lead neurological drug candidate OpenAI Governance and Acquisition Bid Dispute IBTA Ibotta Q4 2025 EPS falls far short of estimates shares dip 213 percent on weak quarterly performance